Company
Every investor coverage indicates participated in a round MPM Capital raised.
Companies MPM Capital acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming MPM Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Leo Pharma has agreed a US$287.5m cash takeover of Peplin, the ASX-listed skin-disease drug developer in GBS Ventures' portfolio; GBS recalls leading its late-2008 round alongside two American venture backers.
LEO Pharma has struck a deal to buy ASX-listed Peplin for roughly US$287.5 million, with its two biggest shareholders, including GBS Venture Partners, backing the transaction.
Also GBS Ventures
ASX-listed biotech Peplin arranged a private placement of roughly US$24 million to advance its keratosis drug into Phase III testing, led by GBS Venture Partners with several existing shareholders also taking part.